Since November 2019, Gremse-IT GmbH is part of the the collaborative project TAKTIRA "Development of an improved immunotherapy with few side effects based on tumor-targeted and activatable immune reaction initiation", which is the follow-up project of the I³-STM. To aim of this project is to develop an improved immunotherapy with few side effects based on tumour-directed and activatable immune reaction triggering. Therefore, several peptide-based immunotherapeutics, so-called "Immune System Engagers (ISErs), are investigated and tested as part of a novel screening system in various cancer models in vitro and in vivo.

Additionally, the consortium consists of 3 partners from Academia (Clinic for Gynecology and Obstetrics, project leader Dr. Jochen Maurer; the Institute for Experimental Molecular Imaging, project leader Univ.-Prof. Dr. Dr. Twan Lammers; and the Institute for Laboratory Animal Science, project leader PD Dr. Julia Steitz, and 3 other SMEs (Syntab Therapeutics GmbH, Black Drop Biodrucker GmbH and TECO Development GmbH from North Rhine-Westphalia, supplemented by the working group of Univ.-Prof. Dr. rer. nat. Christian Becker from the University of Vienna. TAKTIRA is supported by funding from the European Union and the state of North Rhine-Westphalia with a total of €2.85 million.

Within this project, Gremse-IT GmbH develop software methods for the reconstruction, visualization, and quantitative evaluation of multimodal longitudinal image data in order to be able to non-invasively assess drug biodistribution, local accumulation, and effect of tumor-specific and immunotherapeutic agents.

Interesting research results of the project can be found here: "Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles" Biancacci et al. 2021


Biancacci et al. 2021